SEC Form SC 13G filed by Nurix Therapeutics Inc.

11/8/24 10:52:39 AM ET

$NRIX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NRIX alert in real time by email

SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )^*

Nurix Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

67080M103

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]	Rule 13d-1(b)
[ ]	Rule 13d-1(c)
[ ]	Rule 13d-1(d)

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)

CUSIP No.

67080M103

1.	NAMES OF REPORTING PERSONS Wellington Management Group LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	2,642,989
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	3,482,105
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,482,105
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.41%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

67080M103

1.	NAMES OF REPORTING PERSONS Wellington Group Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	2,642,989
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	3,482,105
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,482,105
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.41%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

67080M103

1.	NAMES OF REPORTING PERSONS Wellington Investment Advisors Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	2,642,989
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	3,482,105
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,482,105
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.41%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

67080M103

1.	NAMES OF REPORTING PERSONS Wellington Management Company LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	2,634,261
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	3,222,723
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,222,723
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.00%
12.	TYPE OF REPORTING PERSON IA

Item 1.
	(a)	Name of Issuer Nurix Therapeutics, Inc.
	(b)	Address of Issuer's Principal Executive Offices 1700 Owens Street Suite 205 San Francisco, CA 94158
Item 2.
	(a)	Name of Person Filing Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
	(b)	Address of Principal Business Office or, if None, Residence c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210
	(c)	Citizenship Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
	(d)	Title of Class of Securities Common Stock
	(e)	CUSIP Number 67080M103
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
	(a)	[ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
	(b)	[ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	[ ]	Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	[ ]	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	[X]	An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); *
	(f)	[ ]	An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
	(g)	[X]	A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
	(h)	[ ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	[ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	[ ]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
		If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
	Wellington Management Group LLP - HC Wellington Group Holdings LLP - HC Wellington Investment Advisors Holdings LLP - HC Wellington Management Company LLP - IA
Item 4.	Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount Beneficially Owned:
		See the responses to Item 9 on the attached cover pages.
	(b)	Percent of Class:
		See the responses to Item 11 on the attached cover pages.
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote	0
		(ii)	shared power to vote or to direct the vote	See the responses to Item 6 on the attached cover pages.
		(iii)	sole power to dispose or to direct the disposition of	0
		(iv)	shared power to dispose or to direct the disposition of	See the responses to Item 8 on the attached cover pages.
Item 5.	Ownership of Five Percent or Less of Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
	Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.
	Wellington Group Holdings LLP – HC
	Wellington Investment Advisors LLP – HC
	Wellington Management Global Holdings, Ltd. - HC
	One or more of the following investment advisers (the “Wellington Investment Advisers”):
	Wellington Management Company LLP – IA
	Wellington Management Canada LLC – IA
	Wellington Management Singapore Pte Ltd – IA
	Wellington Management Hong Kong Ltd – IA
	Wellington Management International Ltd – IA
	Wellington Management Japan Pte Ltd – IA
	Wellington Management Australia Pty Ltd - IA
	The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8.	Identification and Classification of Members of the Group. Not Applicable.
Item 9.	Notice of Dissolution of Group. Not Applicable.
Item 10.	Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	By: Wellington Management Group LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

	By: Wellington Group Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

	By: Wellington Investment Advisors Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

	By: Wellington Management Company LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

Get the next $NRIX alert in real time by email

Recent Analyst Ratings for

$NRIX

Date	Price Target	Rating	Analyst
3/17/2025	$16.00	Market Perform	Leerink Partners
12/10/2024	$35.00	Buy	BTIG Research
12/6/2024	$35.00	Outperform	BMO Capital Markets
10/24/2024	$35.00	Buy	UBS
10/11/2024	$41.00	Buy	Jefferies
9/6/2024	$26.00	Outperform	Robert W. Baird
7/31/2024	$36.00	Buy	Truist
6/26/2023	$25.00	Outperform	Oppenheimer

More analyst ratings

SEC Form SC 13G filed by Nurix Therapeutics Inc.

11/8/24 10:52:39 AM ET

$NRIX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NRIX alert in real time by email

SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )^*

Nurix Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

67080M103

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X]	Rule 13d-1(b)
[ ]	Rule 13d-1(c)
[ ]	Rule 13d-1(d)

CUSIP No.

67080M103

1.	NAMES OF REPORTING PERSONS Wellington Management Group LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	2,642,989
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	3,482,105
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,482,105
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.41%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

67080M103

1.	NAMES OF REPORTING PERSONS Wellington Group Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	2,642,989
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	3,482,105
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,482,105
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.41%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

67080M103

1.	NAMES OF REPORTING PERSONS Wellington Investment Advisors Holdings LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	2,642,989
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	3,482,105
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,482,105
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.41%
12.	TYPE OF REPORTING PERSON HC

CUSIP No.

67080M103

1.	NAMES OF REPORTING PERSONS Wellington Management Company LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5. SOLE VOTING POWER	0
		6. SHARED VOTING POWER	2,634,261
		7. SOLE DISPOSITIVE POWER	0
		8. SHARED DISPOSITIVE POWER	3,222,723
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,222,723
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.00%
12.	TYPE OF REPORTING PERSON IA

Item 1.
	(a)	Name of Issuer Nurix Therapeutics, Inc.
	(b)	Address of Issuer's Principal Executive Offices 1700 Owens Street Suite 205 San Francisco, CA 94158
Item 2.
	(a)	Name of Person Filing Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP Wellington Management Company LLP
	(b)	Address of Principal Business Office or, if None, Residence c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210
	(c)	Citizenship Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware Wellington Management Company LLP - Delaware
	(d)	Title of Class of Securities Common Stock
	(e)	CUSIP Number 67080M103
Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
	(a)	[ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
	(b)	[ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	[ ]	Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	[ ]	Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)	[X]	An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); *
	(f)	[ ]	An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
	(g)	[X]	A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
	(h)	[ ]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	[ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	[ ]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
		If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
	Wellington Management Group LLP - HC Wellington Group Holdings LLP - HC Wellington Investment Advisors Holdings LLP - HC Wellington Management Company LLP - IA
Item 4.	Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount Beneficially Owned:
		See the responses to Item 9 on the attached cover pages.
	(b)	Percent of Class:
		See the responses to Item 11 on the attached cover pages.
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote	0
		(ii)	shared power to vote or to direct the vote	See the responses to Item 6 on the attached cover pages.
		(iii)	sole power to dispose or to direct the disposition of	0
		(iv)	shared power to dispose or to direct the disposition of	See the responses to Item 8 on the attached cover pages.
Item 5.	Ownership of Five Percent or Less of Class.
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
	The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows: Not Applicable.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
	Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.
	Wellington Group Holdings LLP – HC
	Wellington Investment Advisors LLP – HC
	Wellington Management Global Holdings, Ltd. - HC
	One or more of the following investment advisers (the “Wellington Investment Advisers”):
	Wellington Management Company LLP – IA
	Wellington Management Canada LLC – IA
	Wellington Management Singapore Pte Ltd – IA
	Wellington Management Hong Kong Ltd – IA
	Wellington Management International Ltd – IA
	Wellington Management Japan Pte Ltd – IA
	Wellington Management Australia Pty Ltd - IA
	The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
Item 8.	Identification and Classification of Members of the Group. Not Applicable.
Item 9.	Notice of Dissolution of Group. Not Applicable.
Item 10.	Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	By: Wellington Management Group LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

	By: Wellington Group Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

	By: Wellington Investment Advisors Holdings LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

	By: Wellington Management Company LLP
	By: /s/ Taisia Lowe
	Name: Taisia Lowe
	Title: Regulatory Analyst
	Date: November 14,2024

Get the next $NRIX alert in real time by email

Recent Analyst Ratings for

$NRIX

Date	Price Target	Rating	Analyst
3/17/2025	$16.00	Market Perform	Leerink Partners
12/10/2024	$35.00	Buy	BTIG Research
12/6/2024	$35.00	Outperform	BMO Capital Markets
10/24/2024	$35.00	Buy	UBS
10/11/2024	$41.00	Buy	Jefferies
9/6/2024	$26.00	Outperform	Robert W. Baird
7/31/2024	$36.00	Buy	Truist
6/26/2023	$25.00	Outperform	Oppenheimer

More analyst ratings

SEC Form SC 13G filed by Nurix Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )*

SIGNATURE

Chat with this insight

Recent Analyst Ratings for $NRIX

SEC Form SC 13G filed by Nurix Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. _ )*

SIGNATURE

Chat with this insight

Recent Analyst Ratings for $NRIX

$NRIX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on Nurix Therapeutics with a new price target

BTIG Research initiated coverage on Nurix Therapeutics with a new price target

BMO Capital Markets initiated coverage on Nurix Therapeutics with a new price target

$NRIX Press Releases

Fastest customizable press release news feed in the world

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

$NRIX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Silva Paul M

SEC Form 4 filed by Director Kunkel Lori Anne

SEC Form 4 filed by Director Gregory Julia P

$NRIX SEC Filings

Nurix Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Nurix Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

$NRIX Leadership Updates

Live Leadership Updates

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

$NRIX Financials

Live finance-specific insights

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

$NRIX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

(Amendment No. _ )^*

Recent Analyst Ratings for
$NRIX

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

(Amendment No. _ )^*

Recent Analyst Ratings for
$NRIX

$NRIX
Analyst Ratings

$NRIX
Press Releases

$NRIX
Insider Trading

$NRIX
SEC Filings

$NRIX
Leadership Updates

$NRIX
Financials

$NRIX
Large Ownership Changes